A succession plan for Biocon has been initiated by Kiran Mazumdar-Shaw. The biotech pioneer predicted that her niece, Claire Mazumdar, would be a successful group leader.
Kiran Mazumdar-Shaw told Fortune India that she believes Claire Mazumdar has the potential to head Biocon in the future. She said that Claire is anticipated to play a bigger part in the group in the future, even though no official timeline has been disclosed.
Mazumdar-Shaw told Fortune India, "I am the sole owner of Biocon, and I need to make sure that I put it in good hands. I have seen my niece Claire as my successor, because I think she has proved to me that she can run a company."
But Kiran Mazumdar Shaw wrote, "Claire will transition into my role at the right time, so not planning to hang up my boots just yet!!" in a series of posts.
In a phone interview with Reuters, Mazumdar-Shaw stated, "I am not hanging up my boots anytime soon, but I want Claire to succeed me in a very phased manner," explaining that the succession would entail a gradual move from director to vice-chair and ultimately chair.
Currently, Claire, 37, is the founder and CEO of Bicara Therapeutics, a biotech startup supported by Biocon.
According to Fortune India, Bicara, whose lead cancer treatment is still undergoing clinical trials, was listed on the Nasdaq in 2024 with a valuation of over USD 800 million and currently commands a market capitalisation of over $1.6 billion.
Claire's solid academic background was noted by Fortune India. She graduated from Massachusetts Institute of Technology with a degree in biological engineering, Stanford Graduate School of Business with an MBA, and Stanford School of Medicine with a PhD in cancer biology. She also worked with Rheos Medicines and Third Rock Ventures before becoming the helm of Bicara.
Kiran Mazumdar-Shaw stated that Claire might potentially seek assistance from other Mazumdar family members. This includes her spouse, Thomas Roberts, an oncologist at Massachusetts General Hospital, and her brother, Eric Mazumdar, an AI specialist who lectures at California Institute of Technology.
According to Fortune India, Biocon recently underwent a significant organisational transformation that included debt reduction, structure simplification, and the merger of its biologics and generics businesses.
According to the Fortune India report, the company's biosimilars division currently accounts for about 60% of its income, with 12 drugs fully commercialised and another 20 more in the works.
Biocon stock was trading at Rs 365.45 on the NSE on Tuesday, up Rs 4.85 or 1.34 per cent, after reports of succession-related developments.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.